Chordia Therapeutics (190A) · TargetRestated
Grow into a research and development-driven pharmaceutical company originating in Japan by 2030
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: 2026-10-15.
3entries
3years
1from disclosures
How it moved
Same theme, other companies
Becoming a Leading Research- and Development-Focused Drug Discovery BiotechA theme 7 companies write about · 0 as a headwind · 8 as a tailwind
The whole theme swung hardest in 2023: 1 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-10-15RestatedEarnings
「The Company has set as its vision becoming a Japan-based R&D pharmaceutical company by 2030」
2030年に日本発の研究開発型製薬会社へ成長するビジョンが再確認された。 - FY2026-H1RestatedAnnual report
「The Company has set as its vision becoming a Japan-based R&D pharmaceutical company by 2030」
The vision of becoming a Japan-based R&D pharmaceutical company by 2030 has been reaffirmed. - FY2024First statedAnnual report
「The Company has set as its vision becoming a Japan-based R&D pharmaceutical company by 2030 through the achievement of this goal.」
A corporate growth vision with 2030 as its target year was stated for the first time.